This study is currently not recruiting participants.

A Multi-center Open-Label Adaptive Randomized Study of Palifosfamide-tris a Novel DNA Crosslinker in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etoposide (CE) Alone in Chemotherapy Naive Patients with Extens

Study of Investigational Medication with Etoposide and Carboplatin for Cancer

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The main purpose of this study is to see if palifosfamide-tris with etoposide and carboplatin can extend the length of time that the cancer is stable and to help patients live longer, compared to treatment with etoposide and carboplatin

Detailed description of study

The main purpose of this study is to see if palifosfamide-tris with etoposide and carboplatin can extend the length of time that the cancer is stable and to help patients live longer, compared to treatment with etoposide and carboplatin

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lung Cancer
  • Age: 18 years - 100 years
  • Gender: All

This study investigates whether an investigational medication combined with etoposide and carboplatin can maintain cancer stability longer and improve survival compared to etoposide and carboplatin alone. This study focuses on understanding the effects of the investigational medication on cancer progression.

Participants will undergo specific procedures to assess the effectiveness of the treatment. These procedures include regular monitoring and assessments to track the progress of the disease and the response to the investigational medication.

  • Who can participate: Participants must be adults aged 18 and older with a confirmed diagnosis of cancer suitable for treatment with etoposide and carboplatin. Key eligibility factors include adequate organ function and no prior treatment with the investigational medication.
  • Study details: Participants will take part in treatment sessions where they will receive either the investigational medication with etoposide, a chemotherapy drug, and carboplatin, another chemotherapy drug, or just etoposide and carboplatin. A placebo will not be used in this study.
Updated on 19 Feb 2024. Study ID: 1205008734

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team